Prism Medico & Pharmacy Ltd
₹ 18.6
1.08%
09 Feb
- close price
About
Incorporated in 1985, Prism Medico & Pharmacy Ltd manufactures, trades, and distributes chemicals, medicines, pharmaceuticals, cosmetics, and related products[1]
Key Points
- Market Cap ₹ 11.3 Cr.
- Current Price ₹ 18.6
- High / Low ₹ 24.8 / 11.6
- Stock P/E 18.5
- Book Value ₹ 24.9
- Dividend Yield 0.00 %
- ROCE -0.40 %
- ROE -0.33 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.75 times its book value
Cons
- The company has delivered a poor sales growth of -52.8% over past five years.
- Promoter holding is low: 25.0%
- Company has a low return on equity of -0.34% over last 3 years.
- Company has high debtors of 2,074 days.
- Working capital days have increased from 4,885 days to 8,551 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.09 | 0.09 | 20.96 | 36.31 | 26.89 | 16.76 | 8.44 | 1.27 | 2.93 | 0.63 | 2.37 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| 0.05 | 0.06 | 0.15 | 0.37 | 20.86 | 35.98 | 26.94 | 16.92 | 8.93 | 1.37 | 3.06 | 0.71 | 1.82 | |
| Financing Profit | -0.05 | -0.06 | -0.06 | -0.28 | 0.10 | 0.33 | -0.05 | -0.16 | -0.49 | -0.10 | -0.14 | -0.08 | 0.55 |
| Financing Margin % | -66.67% | -311.11% | 0.48% | 0.91% | -0.19% | -0.95% | -5.81% | -7.87% | -4.78% | -12.70% | 23.21% | ||
| 0.00 | 0.06 | 0.06 | 0.07 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 | 0.03 | |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.01 | -0.01 | -0.23 | 0.05 | 0.29 | -0.07 | -0.17 | -0.50 | -0.11 | -0.03 | -0.06 | 0.58 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 140.00% | -24.14% | -28.57% | -29.41% | -26.00% | -27.27% | -33.33% | -33.33% | |
| -0.05 | -0.01 | -0.01 | -0.23 | -0.02 | 0.37 | -0.05 | -0.13 | -0.37 | -0.08 | -0.02 | -0.05 | 0.61 | |
| EPS in Rs | -0.25 | -0.05 | -0.05 | -0.38 | -0.03 | 0.61 | -0.08 | -0.21 | -0.61 | -0.13 | -0.03 | -0.08 | 1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -53% |
| 3 Years: | -58% |
| TTM: | -27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 23% |
| TTM: | 1425% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -21% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.99 | 1.99 | 1.99 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | -0.35 | -0.36 | -0.36 | 6.74 | 6.72 | 7.09 | 6.99 | 6.86 | 6.49 | 9.10 | 9.08 | 9.03 |
| Borrowing | 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.02 | 0.04 | 0.16 | 0.25 | 0.16 | 3.82 | 8.54 | 8.63 | 0.02 | 0.23 | 0.10 | 0.47 | |
| Total Liabilities | 1.66 | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 |
| 0.02 | 0.01 | 0.00 | 0.16 | 0.11 | 0.09 | 0.07 | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 10.00 | 11.25 | 10.00 | 1.94 | 1.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.64 | 1.68 | 1.86 | 2.89 | 1.58 | 6.88 | 19.58 | 19.55 | 12.52 | 15.36 | 15.21 | 15.53 | |
| Total Assets | 1.66 | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | 0.01 | 0.05 | -0.82 | -0.06 | -1.23 | -4.36 | -0.05 | -2.38 | 2.95 | -0.01 | -0.02 | |
| 0.03 | 0.00 | 0.46 | 0.30 | -1.25 | 1.25 | 4.36 | 0.02 | 2.35 | -2.91 | 0.00 | 0.00 | |
| 0.00 | 0.02 | 0.05 | 1.33 | -0.05 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | |
| Net Cash Flow | 0.00 | 0.02 | 0.56 | 0.81 | -1.36 | 0.08 | -0.01 | -0.03 | -0.03 | 0.04 | -0.01 | -0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -3.00% | -0.61% | -0.61% | -3.19% | -0.16% | 4.24% | -0.38% | -1.00% | -2.91% | -0.58% | -0.13% | -0.33% |
Documents
Announcements
-
Board Meeting Intimation for Consideration, Approval And Taking On Record The Unaudited Standalone Financial Results Of The Company Along With The Limited Review Report For The Quarter Ended 31St December, 2025.
2d - Board meeting on 13 Feb 2026 to consider unaudited quarter ended 31 Dec 2025 results.
-
Undertaking Of Functional Website
30 Jan - Website updated and functional (https://www.prismmedico.in), notified 28 Jan 2026.
-
Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
16 Jan - Quarterly investor complaints report for period ended 31/12/2025: zero complaints received, pending, or unresolved.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jan - Confirmation certificate under Reg 74(5) for quarter ended 31-Dec-2025; no dematerialisations.
-
Compliance-57 (5) : intimation after the end of quarter
2 Jan - Company confirms no NCS issued and no payments due Oct 1–Dec 31, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
PMPL deals in chemicals, serums, chemical products, antibiotics, medicines, drugs,
pharmaceuticals, pesticides, dyes, soaps, oils, perfumes, cosmetics, patent medicines, etc.